Anti-IL-12 antibodies and compositions
| Title: | Anti-IL-12 antibodies and compositions |
|---|---|
| Patent Number: | 7,887,807 |
| Publication Date: | February 15, 2011 |
| Appl. No: | 12/500120 |
| Application Filed: | July 09, 2009 |
| Abstract: | Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders. |
| Inventors: | Giles-Komar, Jill (Downingtown, PA, US); Knight, David M. (Berwyn, PA, US); Peritt, David (Bala Cynwyd, PA, US); Scallon, Bernard (Collegeville, PA, US); Shealy, David (Downingtown, PA, US) |
| Assignees: | Centocor Ortho Biotech Inc. (Horsham, PA, US) |
| Claim: | 1. An isolated anti-IL-12 antibody, comprising a heavy chain complementarity determining region 1 (CDR1) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:6, wherein the antibody is a variant of the antibody comprising an heavy chain CDR1 amino acid sequence of SEQ ID NO:1, the heavy chain CDR2 amino acid sequence of SEQ ID NO:2, the heavy chain CDR3 amino acid sequence of SEQ ID NO:3, the light chain CDR1 amino acid sequence of SEQ ID NO:4, the light chain CDR2 amino acid sequence of SEQ ID NO:5, and the light chain CDR3 amino acid sequence of SEQ ID NO:6. |
| Claim: | 2. The isolated anti-IL-12 antibody according to claim 1 , comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain CDR3 comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:3, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain CDR3 comprising an amino acid sequence with not more than one conservative substitution from the amino acid sequence of SEQ ID NO:6. |
| Claim: | 3. The isolated anti-IL-12 antibody according to claim 1 , wherein the antibody is human. |
| Claim: | 4. A composition comprising the isolated anti-IL-12 antibody according to claim 1 , and at least one pharmaceutically acceptable carrier or diluent. |
| Claim: | 5. The composition according to claim 4 , further comprising at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist. |
| Claim: | 6. An anti-idiotype antibody or fragment that specifically binds the isolated antibody according to claim 1 . |
| Current U.S. Class: | 4241/451 |
| Patent References Cited: | 5457038 October 1995 Trinchieri et al. 5547852 August 1996 Seller et al. 5648467 July 1997 Trinchieri et al. 5780597 July 1998 Gately et al. 5811523 September 1998 Trinchieri et al. 5891680 April 1999 Lieschke et al. 6086876 July 2000 Karp et al. 6225117 May 2001 Gately et al. 6300478 October 2001 Trinchieri et al. 6338848 January 2002 Leonard et al. 6495667 December 2002 Bazan 6902734 June 2005 Giles-Komar et al. 6914128 July 2005 Salfeld et al. 7166285 January 2007 Giles-Komar et al. 7560247 July 2009 Giles-Komar et al. 790255 August 1997 433827 March 1998 804581 September 2001 WO 90/05147 May 1990 WO 92/05256 April 1992 WO 96/33735 October 1996 WO 97/15327 May 1997 WO 97/15327 May 1997 WO 99/37682 July 1999 WO 00/56772 September 2000 WO 01/19373 March 2001 |
| Other References: | A. U. Gubler et. al (Coexpression of Two Distinct Genes is Required to Generate Secreted Bioactive Cytotoxic Lymphocyte Maturation Factor) Proc. Natl. acad. Sci. USA. vol. 88. pp. 4143-4147-(May 1991) Immunology. cited by other A. U. Gubler et. al (Clonic and Expression of Cytotoxic Lymphocyte Maturation Factor (CLMF) A Heterodimeric Lymphokine That Potentiates Nr. LAK NA D T-Cell Reponses) Abstracts Journal of celluar Biochemistry Supplement 15 F: 70 (1991). cited by other Alvin S. Stern et.al—(Purification to Homogeneity and Partial Characterization of Cytotoxic Lymphocyte Maturation Factor From Human B-Lymphoblastoid Cells) (Jun. 11, 1990) F. Hoffmann La Roche Inc. Nutley NJ USA. Proc. National Acad. Sci. USA (vol. 87,pp. 6808-6812- Sep. 1990- Immunology). cited by other M. Gately et. al. (Regulation of Human Lymphocyte Proliferation by a Heterodimeric Cytokine IL-12 (Cytotoxic Lymphocyte Maturation Factor) vol. 147- 874-882 No. 3. (Aug. 1, 1991).(The Journal of Immunology). cited by other R. Chizzonite et. al. (IL-12 Monoclonal Antibodies Specific for the 40-KdA Subunit Block Receptor Binding and Biologic Activity on Activated Human Lymphoblasts.) vol. 147,1548-1556- No. 5 (Sep. 1, 1991) The Journal of Immunology. cited by other Susan H. Chan et. al. (Introduction of Interferon Production by Natural Killer Cell Stimulatory Factor Characterization of the Responder Cells and Synergy With Other Inducers) (The Rockefeller University Press)- 0022-1007/91/04/0869/-vol. 173 Apr. 1991-pp. 869-879. cited by other Annalisa D'Andrea et. al. (Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cell) J. Exp. Med. The Rockefeller university press- 0022-1007/92/11/1387 vol. 176 Nov. 1992.-pp: 1387-1398. cited by other Markus F. Neurath et. al. (Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice) The Journal of Experimental Medicine—vol. 182- Nov. 1995- pp. 1281-1290. cited by other R.W. Carter. et. al. (Production and Characterization of Monoclonal Antibodies to Human Interleukin-12) Hybriidona 16: 363-369 (1997). cited by other Nicolas M. Valiante et. al. ( Role of the Production of Natural Killer Cell Stimulatory Factor (NKSF/IL-12) in the Ability of B Cell Lines to Stimulate T and NK Cell Proliferation). Cellunar Immunology 145, 187-198-(1992). cited by other Rainer Duchmann et. al. ( Tolerance Towards Resident Intestinal Flora in Mice is Abrogated in Experimental Colitis and Restores by Treatment With Intelukin-1 or Antibodies to Interleukin-12) European Journal of Immunology, 26: 394-938 (1996). cited by other Michiko Kobayashi et. al. I ( Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF) A Cytokine With Multiple Biologic Efects on Human Lymphocytes) J. Exp. Med. The Rockefeller university Press- vol. 170-(Sep. 1989) pp. 827-845. cited by other Sylvie Trembleau et. al. (The Role of IL-12 in the Induction of Organ-Specific Autoimmune Diseases), Immunology Today, 16(8): 383-386 (1995). cited by other Nikhil, Ywalkar et al.; “Expression of interleukin-12 is increased in psoriatic skin”, Journal of Investigative Dermatology, Dec. 1998, pp. 1053-1057; vol. 111, No. 6; XP00800577; ISSN: 0022-202X, abstract. cited by other PCT International Search Report PCT/US01/24720 dated Jul. 30, 2002. cited by other |
| Primary Examiner: | Mertz, Prema |
| Attorney, Agent or Firm: | Dichter, Eric A. |
| Accession Number: | edspgr.07887807 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|